You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH):子公司的單劑量包裝玻璃酸鈉滴眼液獲批上市
格隆匯 07-08 16:26

格隆匯7月8日丨康恩貝(600572.SH)公吿,近日,公司控股子公司江西珍視明藥業有限公司(“珍視明藥業公司”)收到國家藥品監督管理局核准簽發的單劑量包裝0.1%(0.4ml:0.4mg)玻璃酸鈉滴眼液《藥品補充申請批准通知書》。

玻璃酸鈉滴眼液是國內治療乾眼症的常用藥,已列入《國家醫保目錄(2019年版)》,類別為乙類藥品,適用於伴隨下述疾患的角結膜上皮損傷:乾燥綜合徵,斯·約二氏綜合徵,乾眼綜合徵等內因性疾患;手術後、藥物性、外傷、佩戴隱形眼鏡等外因性疾患。

珍視明藥業公司單劑量包裝玻璃酸鈉滴眼液的獲批生產上市,增加了該公司不含抑菌劑的單劑量滴眼液(即一次性使用滴眼液)產品種類,形成了該滴眼液品種多規格的優勢,有利於提高公司在治療乾眼症藥物領域的競爭力,對公司業績將產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account